These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 27389665)

  • 21. Febuxostat--treatment for hyperuricemia and gout?
    Moreland LW
    N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099
    [No Abstract]   [Full Text] [Related]  

  • 22. [Increased uric acid values: when must medication treatment be instituted?].
    Bischoff A
    MMW Fortschr Med; 2010 Jun; 152(23):20. PubMed ID: 20608458
    [No Abstract]   [Full Text] [Related]  

  • 23. Urate oxidase (rasburicase) for treatment of severe acute gout: a case report.
    Wipfler-Freibmuth E; Dejaco C; Duftner C; Gaugg M; Kriessmayr-Lungkofler M; Schirmer M
    Clin Exp Rheumatol; 2009; 27(4):658-60. PubMed ID: 19772802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The current state of care in gout: Addressing the need for better understanding of an ancient disease.
    Zychowicz ME; Pope RS; Graser E
    J Am Acad Nurse Pract; 2010 Nov; 22 Suppl 1():623-36. PubMed ID: 21054636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapy of hyperuricemia and gout].
    Pöllmann G; Kullich W; Klein G
    Wien Med Wochenschr; 1997; 147(16):382-7. PubMed ID: 9446417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
    Wortmann RL; Macdonald PA; Hunt B; Jackson RL
    Clin Ther; 2010 Dec; 32(14):2386-97. PubMed ID: 21353107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.
    Bakris GL; Doghramji PP; Keenan RT; Silber SH
    Am J Med; 2014 Jan; 127(1):S1. PubMed ID: 24268074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hyperuricemia: a laboratory finding needing treatment?].
    Keller C
    Verh Dtsch Ges Inn Med; 1990; 96():188-92. PubMed ID: 2092438
    [No Abstract]   [Full Text] [Related]  

  • 31. [Gout and cardiovascular risk].
    Němec P
    Vnitr Lek; 2014 Oct; 60(10):893-901. PubMed ID: 25382012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis.
    Li S; Yang H; Guo Y; Wei F; Yang X; Li D; Li M; Xu W; Li W; Sun L; Gao Y; Wang Y
    Sci Rep; 2016 Sep; 6():33082. PubMed ID: 27605442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Major unanswered questions in the clinical gout field.
    Stamp LK
    Curr Opin Rheumatol; 2017 Mar; 29(2):171-177. PubMed ID: 27926541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout.
    Steinberg AS; Vince BD; Choi YJ; Martin RL; McWherter CA; Boudes PF
    J Rheumatol; 2017 Mar; 44(3):374-379. PubMed ID: 27980008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hyperuricemia/gout. Main symptoms of arthropathy. Severe acute joint pain, redness, inflammation].
    Kolyvanos Naumann U; Suter PM; Käser L; Vetter W
    Praxis (Bern 1994); 2005 Apr; 94(14):543-8; quiz 549. PubMed ID: 15849976
    [No Abstract]   [Full Text] [Related]  

  • 37. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
    Dalbeth N; Kumar S; Stamp L; Gow P
    J Rheumatol; 2006 Aug; 33(8):1646-50. PubMed ID: 16783857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis.
    Castrejon I; Toledano E; Rosario MP; Loza E; Pérez-Ruiz F; Carmona L
    Rheumatol Int; 2015 Jul; 35(7):1127-37. PubMed ID: 25519877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The year in gout: 2011-2012.
    Crittenden DB; Pillinger MH
    Bull NYU Hosp Jt Dis; 2012; 70(3):145-51. PubMed ID: 23259621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.